HKMPF (Hikma Pharmaceuticals) Book Value per Share: $11.78 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKMPF Hikma Pharmaceuticals PLC HKMPF
82 GF Score
Price $21.26
GF Value $28.54
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikma Pharmaceuticals Book Value per Share?

Hikma Pharmaceuticals HKMPF -2.01% 82 Book Value per Share is $11.78 as of Dec. 2025. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $28.54 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Hikma Pharmaceuticals's book value per share for the quarter that ended in Dec. 2025 was $11.78.

During the past 12 months, Hikma Pharmaceuticals's average Book Value Per Share Growth Rate was 6.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 3.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 3.90% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Hikma Pharmaceuticals was 75.30% per year. The lowest was -5.90% per year. And the median was 13.10% per year.

Hikma Pharmaceuticals's current price is $21.26. Its book value per share for the quarter that ended in Dec. 2025 was $11.78. Hence, today's PB Ratio of Hikma Pharmaceuticals is 1.80.

During the past 13 years, the highest P/B Ratio of Hikma Pharmaceuticals was 5.90. The lowest was 1.24. And the median was 2.54.


Hikma Pharmaceuticals  (OTCPK:HKMPF) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Hikma Pharmaceuticals Book Value per Share Related Terms


Hikma Pharmaceuticals Book Value per Share Historical Data

* Premium members only.

The historical data trend for Hikma Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hikma Pharmaceuticals Book Value per Share Chart

Hikma Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.60 9.69 9.94 10.48 11.78

Hikma Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.94 10.31 10.48 11.46 11.78

HKMPF vs ZTS, UTHR, VTRS: Book Value per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hikma Pharmaceuticals PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Hikma Pharmaceuticals's PB Ratio falls into.


HKMPF
82GF Score
Hikma Pharmaceuticals PLC HKMPF
Book Value per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hikma Pharmaceuticals Book Value per Share Calculation

Hikma Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(2,593-0)/220
=11.78

Hikma Pharmaceuticals's Book Value Per Share for the quarter that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(2,593-0)/220
=11.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $11.78 mean?
Hikma Pharmaceuticals (HKMPF) has a Book Value per Share of $11.78 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Hikma Pharmaceuticals and its competitors.
Is Hikma Pharmaceuticals' Book Value per Share too high?
Hikma Pharmaceuticals' current Book Value per Share is $11.78. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Book Value per Share compare to ZTS and UTHR?
Hikma Pharmaceuticals' Book Value per Share of $11.78 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Book Value per Share is $11.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.54, compared to a current price of $21.26 — trading 25.5% below its estimated fair value. The current Book Value per Share is $11.78. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current Book Value per Share is $11.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?

Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued. The current stock price of $21.26 is trading 25.5% below its estimated GF Value™ of $28.54. GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKMPF:

  • Book Value per Share: $11.78
  • GF Value™: $28.54 vs. price of $21.26 (25.5% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hikma Pharmaceuticals Business Description

Address 10 Portman Square, London, GBR, W1H 6AZ
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score

Get the complete analysis for HKMPF

Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.26
Price
$28.54
GF Value